Jeffrey Schlom

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Living Beings

Chemicals & Drugs

Disorders

Anatomy

Physiology

Lymphocyte Activation

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Cereda Vittore; Poole Diane J; Palena Claudia; Das Sudipto; Bera Tapan K; Remondo Cinzia; Gulley James L; Arlen Philip M; Yokokawa Junko; Pastan Ira; Schlom Jeffrey; Tsang Kwong Y
New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy.
di Bari Maria Giovanna; Lutsiak M E Christine; Takai Shinji; Mostböck Sven; Farsaci Benedetto; Semnani Roshanak Tolouei; Wakefield Lalage M; Schlom Jeffrey; Sabzevari Helen
TGF-beta modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression.
Zaharoff David A; Hoffman Benjamin S; Hooper H Brooks; Benjamin Compton J; Khurana Kiranpreet K; Hance Kenneth W; Rogers Connie J; Pinto Peter A; Schlom Jeffrey; Greiner John W
Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Jeffrey Schlom (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2010: Cereda Vittore; Poole Diane J; Palena Claudia; Das Sudipto; Bera Tapan K; Remondo Cinzia; Gulley James L; Arlen Philip M; Yokokawa Junko; Pastan Ira; Schlom Jeffrey; Tsang Kwong Y
New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy.
Cancer immunology, immunotherapy : CII 2010;59(1):63-71.
2009: di Bari Maria Giovanna; Lutsiak M E Christine; Takai Shinji; Mostböck Sven; Farsaci Benedetto; Semnani Roshanak Tolouei; Wakefield Lalage M; Schlom Jeffrey; Sabzevari Helen
TGF-beta modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression.
Cancer immunology, immunotherapy : CII 2009;58(11):1809-18.
2009: Zaharoff David A; Hoffman Benjamin S; Hooper H Brooks; Benjamin Compton J; Khurana Kiranpreet K; Hance Kenneth W; Rogers Connie J; Pinto Peter A; Schlom Jeffrey; Greiner John W
Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12.
Cancer research 2009;69(15):6192-9.
2009: Hodge James W; Higgins Jack; Schlom Jeffrey
Harnessing the unique local immunostimulatory properties of modified vaccinia Ankara (MVA) virus to generate superior tumor-specific immune responses and antitumor activity in a diversified prime and boost vaccine regimen.
Vaccine 2009;27(33):4475-82.
2009: Litzinger Mary T; Foon Kenneth A; Sabzevari Helen; Tsang Kwong-Yok; Schlom Jeffrey; Palena Claudia
Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients.
Cancer immunology, immunotherapy : CII 2009;58(6):955-65.
2009: Hance Kenneth W; Rogers Connie J; Zaharoff David A; Canter Daniel; Schlom Jeffrey; Greiner John W
The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(7):2387-96.
2009: Yang Sixun; Schlom Jeffrey
Antigen-presenting cells containing multiple costimulatory molecules promote activation and expansion of human antigen-specific memory CD8+ T cells.
Cancer immunology, immunotherapy : CII 2009;58(4):503-15.
2009: Remondo Cinzia; Cereda Vittore; Mostböck Sven; Sabzevari Helen; Franzusoff Alex; Schlom Jeffrey; Tsang Kwong-Y
Human dendritic cell maturation and activation by a heat-killed recombinant yeast (Saccharomyces cerevisiae) vector encoding carcinoembryonic antigen.
Vaccine 2009;27(7):987-94.
2008: Rogers Connie J; Zaharoff David A; Hance Kenneth W; Perkins Susan N; Hursting Stephen D; Schlom Jeffrey; Greiner John W
Exercise enhances vaccine-induced antigen-specific T cell responses.
Vaccine 2008;26(42):5407-15.
2008: Cheever Martin A; Schlom Jeffrey; Weiner Louis M; Lyerly H Kim; Disis Mary L; Greenwood Addison; Grad Oren; Nelson William G;
Translational Research Working Group developmental pathway for immune response modifiers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(18):5692-9.
2008: Lechleider Robert J; Arlen Philip M; Tsang Kwong-Yok; Steinberg Seth M; Yokokawa Junko; Cereda Vittore; Camphausen Kevin; Schlom Jeffrey; Dahut William L; Gulley James L
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(16):5284-91.
2008: Chakraborty Mala; Gelbard Alexander; Carrasquillo Jorge A; Yu Sarah; Mamede Marcelo; Paik Chang H; Camphausen Kevin; Schlom Jeffrey; Hodge James W
Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects.
Cancer immunology, immunotherapy : CII 2008;57(8):1173-83.
2008: Madan Ravi A; Gulley James L; Schlom Jeffrey; Steinberg Seth M; Liewehr David J; Dahut William L; Arlen Philip M
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(14):4526-31.
2008: Wansley Elizabeth K; Chakraborty Mala; Hance Kenneth W; Bernstein Michael B; Boehm Amanda L; Guo Zhimin; Quick Deborah; Franzusoff Alex; Greiner John W; Schlom Jeffrey; Hodge James W
Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(13):4316-25.
2008: Chakraborty Mala; Wansley Elizabeth K; Carrasquillo Jorge A; Yu Sarah; Paik Chang H; Camphausen Kevin; Becker Michael D; Goeckeler William F; Schlom Jeffrey; Hodge James W
The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(13):4241-9.
2008: Garnett Charlie T; Schlom Jeffrey; Hodge James W
Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3536-44.
2008: Gulley James L; Arlen Philip M; Tsang Kwong-Yok; Yokokawa Junko; Palena Claudia; Poole Diane J; Remondo Cinzia; Cereda Vittore; Jones Jacquin L; Pazdur Mary P; Higgins Jack P; Hodge James W; Steinberg Seth M; Kotz Herbert; Dahut William L; Schlom Jeffrey
Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(10):3060-9.
2008: Lutsiak M E Christine; Tagaya Yutaka; Adams Anthony J; Schlom Jeffrey; Sabzevari Helen
Tumor-induced impairment of TCR signaling results in compromised functionality of tumor-infiltrating regulatory T cells.
Journal of immunology (Baltimore, Md. : 1950) 2008;180(9):5871-81.
2008: Schlom Jeffrey; Gulley James L; Arlen Philip M
Paradigm shifts in cancer vaccine therapy.
Experimental biology and medicine (Maywood, N.J.) 2008;233(5):522-34.
2008: Mostböck Sven; Lutsiak M E Christine; Milenic Diane E; Baidoo Kwamena; Schlom Jeffrey; Sabzevari Helen
IL-2/anti-IL-2 antibody complex enhances vaccine-mediated antigen-specific CD8(+) T cell responses and increases the ratio of effector/memory CD8(+) T cells to regulatory T cells.
Journal of immunology (Baltimore, Md. : 1950) 2008;180(7):5118-29.
2008: Yokokawa Junko; Cereda Vittore; Remondo Cinzia; Gulley James L; Arlen Philip M; Schlom Jeffrey; Tsang Kwong Y
Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(4):1032-40.
2008: Zeytin Hasan; Reali Eva; Zaharoff David A; Rogers Connie J; Schlom Jeffrey; Greiner John W
Targeted delivery of murine IFN-gamma using a recombinant fowlpox virus: NK cell recruitment to regional lymph nodes and priming of tumor-specific host immunity.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2008;28(2):73-87.
2008: Rogers Connie J; Berrigan David; Zaharoff David A; Hance Kenneth W; Patel Arti C; Perkins Susan N; Schlom Jeffrey; Greiner John W; Hursting Stephen D
Energy restriction and exercise differentially enhance components of systemic and mucosal immunity in mice.
The Journal of nutrition 2008;138(1):115-22.
2008: Bernstein Michael B; Chakraborty Mala; Wansley Elizabeth K; Guo Zhimin; Franzusoff Alex; Mostböck Sven; Sabzevari Helen; Schlom Jeffrey; Hodge James W
Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells.
Vaccine 2008;26(4):509-21.
2007: Zaharoff David A; Rogers Connie J; Hance Kenneth W; Schlom Jeffrey; Greiner John W
Chitosan solution enhances the immunoadjuvant properties of GM-CSF.
Vaccine 2007;25(52):8673-86.
2007: Kudo-Saito Chie; Garnett Charlie T; Wansley Elizabeth K; Schlom Jeffrey; Hodge James W
Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity.
Cancer immunology, immunotherapy : CII 2007;56(12):1897-910.
2007: Litzinger Mary T; Fernando Romaine; Curiel Tyler J; Grosenbach Douglas W; Schlom Jeffrey; Palena Claudia
IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.
Blood 2007;110(9):3192-201.
2007: Arlen Philip M; Skarupa Lisa; Pazdur Mary; Seetharam Mahesh; Tsang Kwong Y; Grosenbach Douglas W; Feldman Jarett; Poole Diane J; Litzinger Mary; Steinberg Seth M; Jones Elizabeth; Chen Clara; Marte Jennifer; Parnes Howard; Wright John; Dahut William; Schlom Jeffrey; Gulley James L
Clinical safety of a viral vector based prostate cancer vaccine strategy.
The Journal of urology 2007;178(4 Pt 1):1515-20.
2007: Mostböck Sven; Vidal Silvia; Schlom Jeffrey; Sabzevari Helen
Enhanced levels of costimulation lead to reduced effector/memory CD8+ T cell functionality.
Journal of immunology (Baltimore, Md. : 1950) 2007;179(6):3524-34.
2007: Chakraborty Mala; Schlom Jeffrey; Hodge James W
The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses.
Cancer immunology, immunotherapy : CII 2007;56(9):1471-84.
2007: Yokokawa Junko; Bera Tapan K; Palena Claudia; Cereda Vittore; Remondo Cinzia; Gulley James L; Arlen Philip M; Pastan Ira; Schlom Jeffrey; Tsang Kwong Y
Identification of cytotoxic T-lymphocyte epitope(s) and its agonist epitope(s) of a novel target for vaccine therapy (PAGE4).
International journal of cancer. Journal international du cancer 2007;121(3):595-605.
2007: Schlom Jeffrey; Arlen Philip M; Gulley James L
Cancer vaccines: moving beyond current paradigms.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(13):3776-82.
2007: Theoret Marc R; Arlen Philip M; Pazdur Mary; Dahut William L; Schlom Jeffrey; Gulley James L
Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer.
Clinical genitourinary cancer 2007;5(5):347-50.
2007: Palena Claudia; Polev Dmitry E; Tsang Kwong Y; Fernando Romaine I; Litzinger Mary; Krukovskaya Larisa L; Baranova Ancha V; Kozlov Andrei P; Schlom Jeffrey
The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(8):2471-8.
2007: Kudo-Saito Chie; Wansley Elizabeth K; Gruys M Eilene; Wiltrout Robert; Schlom Jeffrey; Hodge James W
Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1936-46.
2007: Zaharoff David A; Rogers Connie J; Hance Kenneth W; Schlom Jeffrey; Greiner John W
Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination.
Vaccine 2007;25(11):2085-94.
2007: Mostböck Sven; Catalfamo Marta; Tagaya Yutaka; Schlom Jeffrey; Sabzevari Helen
Acquisition of antigen presentasome (APS), an MHC/costimulatory complex, is a checkpoint of memory T-cell homeostasis.
Blood 2007;109(6):2488-95.
2007: O'Mahony Deirdre; Morris John C; Quinn Cate; Gao Wendy; Wilson Wyndham H; Gause Barry; Pittaluga Stefania; Neelapu Sattva; Brown Margaret; Fleisher Thomas A; Gulley James L; Schlom Jeffrey; Nussenblatt Robert; Albert Paul; Davis Thomas A; Lowy Israel; Petrus Mike; Waldmann Thomas A; Janik John E
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(3):958-64.
2007: Arlen Philip M; Gulley James L; Madan Ravi A; Hodge James W; Schlom Jeffrey
Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy.
Critical reviews in immunology 2007;27(5):451-62.
2007: Sharp Hadley J; Wansley Elizabeth K; Garnett Charlie T; Chakraborty Mala; Camphausen Kevin; Schlom Jeffrey; Hodge James W
Synergistic antitumor activity of immune strategies combined with radiation.
Frontiers in bioscience : a journal and virtual library 2007;12():4900-10.
2006: Kudo-Saito Chie; Hodge James W; Kwak Heesun; Kim-Schulze Seunghee; Schlom Jeffrey; Kaufman Howard L
4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.
Vaccine 2006;24(23):4975-86.
2006: Reits Eric A; Hodge James W; Herberts Carla A; Groothuis Tom A; Chakraborty Mala; Wansley Elizabeth K; Camphausen Kevin; Luiten Rosalie M; de Ru Arnold H; Neijssen Joost; Griekspoor Alexander; Mesman Elly; Verreck Frank A; Spits Hergen; Schlom Jeffrey; van Veelen Peter; Neefjes Jacques J
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.
The Journal of experimental medicine 2006;203(5):1259-71.
2006: Chinn Paul C; Morena Ron A; Santoro Denise A; Kazules Timothy; Kashmiri Syed V S; Schlom Jeffrey; Hanna Nabil; Braslawsky Gary
Pharmacokinetics and tumor localization of (111)in-labeled HuCC49DeltaC(H)2 in BALB/c mice and athymic murine colon carcinoma xenograft.
Cancer biotherapy & radiopharmaceuticals 2006;21(2):106-16.
2006: Gelbard Alexander; Garnett Charlie T; Abrams Scott I; Patel Vyomesh; Gutkind J Silvio; Palena Claudia; Tsang Kwong-Yok; Schlom Jeffrey; Hodge James W
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(6):1897-905.
2006: Arlen Philip M; Gulley James L; Parker Catherine; Skarupa Lisa; Pazdur Mary; Panicali Dennis; Beetham Patricia; Tsang Kwong Y; Grosenbach Douglas W; Feldman Jarett; Steinberg Seth M; Jones Elizabeth; Chen Clara; Marte Jennifer; Schlom Jeffrey; Dahut William
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(4):1260-9.
2006: Kaufman Howard L; Cohen Seth; Cheung Ken; DeRaffele Gail; Mitcham Josephine; Moroziewicz Dorota; Schlom Jeffrey; Hesdorffer Charles
Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors.
Human gene therapy 2006;17(2):239-44.
2006: Palena Claudia; Abrams Scott I; Schlom Jeffrey; Hodge James W
Cancer vaccines: preclinical studies and novel strategies.
Advances in cancer research 2006;95():115-45.
2006: Garnett Charlie T; Greiner John W; Tsang Kwong-Yok; Kudo-Saito Chie; Grosenbach Douglas W; Chakraborty Mala; Gulley James L; Arlen Philip M; Schlom Jeffrey; Hodge James W
TRICOM vector based cancer vaccines.
Current pharmaceutical design 2006;12(3):351-61.
2006: Hodge James W; Greiner John W; Tsang Kwong-Yok; Sabzevari Helen; Kudo-Saito Chie; Grosenbach Douglas W; Gulley James L; Arlen Philip M; Marshall John L; Panicali Dennis; Schlom Jeffrey
Costimulatory molecules as adjuvants for immunotherapy.
Frontiers in bioscience : a journal and virtual library 2006;11():788-803.
2005: Palena Claudia; Foon Kenneth A; Panicali Dennis; Yafal Alicia Gómez; Chinsangaram Jarasvech; Hodge James W; Schlom Jeffrey; Tsang Kwong Y
Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules.
Blood 2005;106(10):3515-23.
2005: Yang Sixun; Hodge James W; Grosenbach Douglas W; Schlom Jeffrey
Vaccines with enhanced costimulation maintain high avidity memory CTL.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(6):3715-23.
2005: Yokokawa Junko; Palena Claudia; Arlen Philip; Hassan Raffit; Ho Mitchell; Pastan Ira; Schlom Jeffrey; Tsang Kwong Y
Identification of novel human CTL epitopes and their agonist epitopes of mesothelin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(17):6342-51.
2005: Yang Sixun; Tsang Kwong-Yok; Schlom Jeffrey
Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(15):5603-15.
2005: Arlen Philip M; Gulley James L; Todd Nushin; Lieberman Ronald; Steinberg Seth M; Morin Steve; Bastian Anne; Marte Jennifer; Tsang Kwong-Yok; Beetham Patricia; Grosenbach Douglas W; Schlom Jeffrey; Dahut William
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.
The Journal of urology 2005;174(2):539-46.
2005: Kudo-Saito Chie; Schlom Jeffrey; Camphausen Kevin; Coleman C Norman; Hodge James W
The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(12):4533-44.
2005: Hodge James W; Chakraborty Mala; Kudo-Saito Chie; Garnett Charlie T; Schlom Jeffrey
Multiple costimulatory modalities enhance CTL avidity.
Journal of immunology (Baltimore, Md. : 1950) 2005;174(10):5994-6004.
2005: Gulley James L; Arlen Philip M; Bastian Anne; Morin Steven; Marte Jennifer; Beetham Patricia; Tsang Kwong-Yok; Yokokawa Junko; Hodge James W; Ménard Cynthia; Camphausen Kevin; Coleman C Norman; Sullivan Francis; Steinberg Seth M; Schlom Jeffrey; Dahut William
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3353-62.
2005: Kashmiri Syed V S; De Pascalis Roberto; Gonzales Noreen R; Schlom Jeffrey
SDR grafting--a new approach to antibody humanization.
Methods (San Diego, Calif.) 2005;36(1):25-34.
2005: Morse Michael A; Clay Timothy M; Hobeika Amy C; Osada Takuya; Khan Shubi; Chui Stephen; Niedzwiecki Donna; Panicali Dennis; Schlom Jeffrey; Lyerly H Kim
Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(8):3017-24.
2005: Reali E; Canter D; Zeytin H; Schlom J; Greiner J W
Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms.
Vaccine 2005;23(22):2909-21.
2005: Zhou Jun; Tagaya Yutaka; Tolouei-Semnani Roshanak; Schlom Jeffrey; Sabzevari Helen
Physiological relevance of antigen presentasome (APS), an acquired MHC/costimulatory complex, in the sustained activation of CD4+ T cells in the absence of APCs.
Blood 2005;105(8):3238-46.
2005: Lutsiak M E Christine; Semnani Roshanak T; De Pascalis Roberto; Kashmiri Syed V S; Schlom Jeffrey; Sabzevari Helen
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.
Blood 2005;105(7):2862-8.
2005: Kudo-Saito Chie; Schlom Jeffrey; Hodge James W
Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(6):2416-26.
2005: Tsang Kwong Y; Palena Claudia; Yokokawa Junko; Arlen Philip M; Gulley James L; Mazzara Gail P; Gritz Linda; Yafal Alicia Gómez; Ogueta Sandra; Greenhalgh Patricia; Manson Kelledy; Panicali Dennis; Schlom Jeffrey
Analyses of recombinant vaccinia and fowlpox vaccine vectors expressing transgenes for two human tumor antigens and three human costimulatory molecules.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(4):1597-607.
2005: Marshall John L; Gulley James L; Arlen Philip M; Beetham Patricia K; Tsang Kwong-Yok; Slack Rebecca; Hodge James W; Doren Sandra; Grosenbach Douglas W; Hwang Jimmy; Fox Evelyn; Odogwu Lauretta; Park Susie; Panicali Dennis; Schlom Jeffrey
Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(4):720-31.
2005: Gonzales Noreen R; De Pascalis Roberto; Schlom Jeffrey; Kashmiri Syed V S
Minimizing the immunogenicity of antibodies for clinical application.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2005;26(1):31-43.
2004: Garnett Charlie T; Palena Claudia; Chakraborty Mala; Tsang Kwong-Yok; Schlom Jeffrey; Hodge James W
Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes.
Cancer research 2004;64(21):7985-94.
2004: Slavin-Chiorini Dale C; Catalfamo Marta; Kudo-Saito Chie; Hodge James W; Schlom Jeffrey; Sabzevari Helen
Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy.
Cancer gene therapy 2004;11(10):665-80.
2004: Belardelli Filippo; Ferrantini Maria; Parmiani Giorgio; Schlom Jeffrey; Garaci Enrico
International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines?
Cancer research 2004;64(18):6827-30.
2004: Gonzales Noreen R; Padlan Eduardo A; De Pascalis Roberto; Schuck Peter; Schlom Jeffrey; Kashmiri Syed V S
SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity.
Molecular immunology 2004;41(9):863-72.
2004: Palena Claudia; Zhu MingZhu; Schlom Jeffrey; Tsang Kwong-Yok
Human B cells that hyperexpress a triad of costimulatory molecules via avipox-vector infection: an alternative source of efficient antigen-presenting cells.
Blood 2004;104(1):192-9.
2004: Chakraborty Mala; Abrams Scott I; Coleman C Norman; Camphausen Kevin; Schlom Jeffrey; Hodge James W
External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing.
Cancer research 2004;64(12):4328-37.
2004: Kaufman Howard L; Wang Wei; Manola Judith; DiPaola Robert S; Ko Yoo-Joung; Sweeney Christopher; Whiteside Theresa L; Schlom Jeffrey; Wilding George; Weiner Louis M
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(11):2122-32.
2004: Zeytin Hasan E; Patel Arti C; Rogers Connie J; Canter Daniel; Hursting Stephen D; Schlom Jeffrey; Greiner John W
Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice.
Cancer research 2004;64(10):3668-78.
2004: Milenic Diane; Garmestani Kayhan; Dadachova Ekaterina; Chappell Lara; Albert Paul; Hill Donald; Schlom Jeffrey; Brechbiel Martin
Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody.
Cancer biotherapy & radiopharmaceuticals 2004;19(2):135-47.
2004: Tsang Kwong-Yok; Palena Claudia; Gulley James; Arlen Philip; Schlom Jeffrey
A human cytotoxic T-lymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(6):2139-49.
2004: Kudo-Saito Chie; Schlom Jeffrey; Hodge James W
Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(3):1090-9.
2004: Schlom J; Palena C; Greiner J W; Tsang K Y; Grosenbach D W; Sabzevari H; Gulley J L; Arlen P M; Kass E; Hodge J W
Combinatorial vaccine strategies and the use of molecular arrays to characterize T-cell activation.
Developments in biologicals 2004;116():27-47.
2003: De Pascalis Roberto; Gonzales Noreen R; Padlan Eduardo A; Schuck Peter; Batra Surinder K; Schlom Jeffrey; Kashmiri Syed V S
In vitro affinity maturation of a specificity-determining region-grafted humanized anticarcinoma antibody: isolation and characterization of minimally immunogenic high-affinity variants.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(15):5521-31.
2003: Hodge James W; Poole Diane J; Aarts Wilhelmina M; Gómez Yafal Alicia; Gritz Linda; Schlom Jeffrey
Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
Cancer research 2003;63(22):7942-9.
2003: Palena Claudia; Arlen Philip; Zeytin Hasan; Greiner John W; Schlom Jeffrey; Tsang Kwong-Yok
Enhanced expression of lymphotactin by CD8+ T cells is selectively induced by enhancer agonist peptides of tumor-associated antigens.
Cytokine 2003;24(4):128-42.
2003: Forero Andres; Meredith Ruby F; Khazaeli M B; Carpenter D Mark; Shen Sui; Thornton Jennifer; Schlom Jeffrey; LoBuglio Albert F
A novel monoclonal antibody design for radioimmunotherapy.
Cancer biotherapy & radiopharmaceuticals 2003;18(5):751-9.
2003: Gonzales Noreen R; Padlan Eduardo A; De Pascalis Roberto; Schuck Peter; Schlom Jeffrey; Kashmiri S V S
Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues.
Molecular immunology 2003;40(6):337-49.
2003: Arlen Philip M; Gulley James L; Tsang Kwong-Yok; Schlom Jeffrey
Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.
Expert review of vaccines 2003;2(4):483-93.
2003: Arlen Philip M; Gulley James L; Palena Claudia; Marshall John; Schlom Jeffrey; Tsang Kwong Yok
A novel ELISPOT assay to enhance detection of antigen-specific T cells employing antigen-presenting cells expressing vector-driven human B7-1.
Journal of immunological methods 2003;279(1-2):183-92.
2003: Morse Michael A; Nair Smita K; Mosca Paul J; Hobeika Amy C; Clay Timothy M; Deng Yuping; Boczkowski David; Proia Alan; Neidzwiecki Donna; Clavien Pierre-A; Hurwitz Herbert I; Schlom Jeffrey; Gilboa Eli; Lyerly H Kim
Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA.
Cancer investigation 2003;21(3):341-9.
2003: Schlom J; Sabzevari H; Grosenbach D W; Hodge J W
A triad of costimulatory molecules synergize to amplify T-cell activation in both vector-based and vector-infected dendritic cell vaccines.
Artificial cells, blood substitutes, and immobilization biotechnology 2003;31(2):193-228.
2003: Hodge James W; Grosenbach Douglas W; Aarts Wilhelmina M; Poole Diane J; Schlom Jeffrey
Vaccine therapy of established tumors in the absence of autoimmunity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(5):1837-49.
2003: Palena Claudia; Schlom Jeffrey; Tsang Kwong-Yok
Differential gene expression profiles in a human T-cell line stimulated with a tumor-associated self-peptide versus an enhancer agonist peptide.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(5):1616-27.
2003: Grosenbach Douglas W; Schlom Jeffrey; Gritz Linda; Gómez Yafal Alicia; Hodge James W
A recombinant vector expressing transgenes for four T-cell costimulatory molecules (OX40L, B7-1, ICAM-1, LFA-3) induces sustained CD4+ and CD8+ T-cell activation, protection from apoptosis, and enhanced cytokine production.
Cellular immunology 2003;222(1):45-57.
2003: Oh SangKon; Hodge James W; Ahlers Jeffrey D; Burke Donald S; Schlom Jeffrey; Berzofsky Jay A
Selective induction of high avidity CTL by altering the balance of signals from APC.
Journal of immunology (Baltimore, Md. : 1950) 2003;170(5):2523-30.
2003: Hodge James W; Tsang Kwong-Yok; Poole Diane J; Schlom Jeffrey
General keynote: vaccine strategies for the therapy of ovarian cancer.
Gynecologic oncology 2003;88(1 Pt 2):S97-104; discussion S110-3.
2002: Greiner John W; Zeytin Hasan; Anver Miriam R; Schlom Jeffrey
Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity.
Cancer research 2002;62(23):6944-51.
2002: Tatari-Calderone Zohreh; Semnani Roshanak Tolouei; Nutman Thomas B; Schlom Jeffrey; Sabzevari Helen
Acquisition of CD80 by human T cells at early stages of activation: functional involvement of CD80 acquisition in T cell to T cell interaction.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(11):6162-9.
2002: Aarts Wilhelmina M; Schlom Jeffrey; Hodge James W
Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
Cancer research 2002;62(20):5770-7.
2002: Gulley James; Chen Alice P; Dahut William; Arlen Philip M; Bastian Anne; Steinberg Seth M; Tsang Kwong; Panicali Dennis; Poole Diane; Schlom Jeffrey; Michael Hamilton J
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
The Prostate 2002;53(2):109-17.
2002: Gonzales Noreen R; Schuck Peter; Schlom Jeffrey; Kashmiri Syed V S
Surface plasmon resonance-based competition assay to assess the sera reactivity of variants of humanized antibodies.
Journal of immunological methods 2002;268(2):197-210.
2002: Alvarez Ronald D; Huh Warner K; Khazaeli M B; Meredith Ruby F; Partridge Edward E; Kilgore Larry C; Grizzle William E; Shen Sui; Austin J Max; Barnes Mack N; Carey Delicia; Schlom Jeffrey; LoBuglio Albert F
A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(9):2806-11.
2002: De Pascalis Roberto; Iwahashi Makoto; Tamura Midori; Padlan Eduardo A; Gonzales Noreen R; Santos Ameurfina D; Giuliano Mariateresa; Schuck Peter; Schlom Jeffrey; Kashmiri Syed V S
Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(6):3076-84.
2002: Schmitz John; Reali Eva; Hodge James W; Patel Arti; Davis Garland; Schlom Jeffrey; Greiner John W
Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice.
Cancer research 2002;62(17):5058-64.
2002: Kass Erik S; Greiner John W; Kantor Judith A; Tsang Kwong Y; Guadagni Fiorella; Chen Zhong; Clark Bradly; De Pascalis Roberto; Schlom Jeffrey; Van Waes Carter
Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer.
Cancer research 2002;62(17):5049-57.
2002: Milenic Diane E; Garmestani Kayhan; Chappell Lara L; Dadachova Ekaterina; Yordanov Alexander; Ma Dangshe; Schlom Jeffrey; Brechbiel Martin W
In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications.
Nuclear medicine and biology 2002;29(4):431-42.
2002: Kennel Stephen J; Brechbiel Martin W; Milenic Diane E; Schlom Jeffrey; Mirzadeh Saed
Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49.
Cancer biotherapy & radiopharmaceuticals 2002;17(2):219-31.
2002: Terasawa Hiroshi; Tsang Kwong-Yok; Gulley James; Arlen Philip; Schlom Jeffrey
Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(1):41-53.
2002: Morse Michael A; Nair Smita K; Boczkowski David; Tyler Douglas; Hurwitz Herbert I; Proia Alan; Clay Timothy M; Schlom Jeffrey; Gilboa Eli; Lyerly H Kim
The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer.
International journal of gastrointestinal cancer 2002;32(1):1-6.
2002: Hodge James W; Grosenbach Douglas W; Schlom Jeffrey
Vector-based delivery of tumor-associated antigens and T-cell co-stimulatory molecules in the induction of immune responses and anti-tumor immunity.
Cancer detection and prevention 2002;26(4):275-91.
2001: Shankar P; Schlom J; Hodge J W
Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3).
Vaccine 2001;20(5-6):744-55.
2001: Tsang K Y; Zhu M; Even J; Gulley J; Arlen P; Schlom J
The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.
Cancer research 2001;61(20):7568-76.
2001: Meredith R F; Alvarez R D; Partridge E E; Khazaeli M B; Lin C Y; Macey D J; Austin J M; Kilgore L C; Grizzle W E; Schlom J; LoBuglio A F
Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study.
Cancer biotherapy & radiopharmaceuticals 2001;16(4):305-15.
2001: Reali E; Greiner J W; Corti A; Gould H J; Bottazzoli F; Paganelli G; Schlom J; Siccardi A G
IgEs targeted on tumor cells: therapeutic activity and potential in the design of tumor vaccines.
Cancer research 2001;61(14):5517-22.
2001: Rad A N; Schlom J; Hodge J W
Vector-driven hyperexpression of a triad of costimulatory molecules confers enhanced T-cell stimulatory capacity to DC precursors.
Critical reviews in oncology/hematology 2001;39(1-2):43-57.
2001: Grosenbach D W; Barrientos J C; Schlom J; Hodge J W
Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.
Cancer research 2001;61(11):4497-505.
2001: Hodge J W; Grosenbach D W; Rad A N; Giuliano M; Sabzevari H; Schlom J
Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules.
Vaccine 2001;19(25-26):3552-67.
2001: Zhu M; Terasawa H; Gulley J; Panicali D; Arlen P; Schlom J; Tsang K Y
Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells.
Cancer research 2001;61(9):3725-34.
2001: Milenic D E; Roselli M; Mirzadeh S; Pippin C G; Gansow O A; Colcher D; Brechbiel M W; Schlom J
In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates.
Cancer biotherapy & radiopharmaceuticals 2001;16(2):133-46.
2001: Kashmiri S V; Iwahashi M; Tamura M; Padlan E A; Milenic D E; Schlom J
Development of a minimally immunogenic variant of humanized anti-carcinoma monoclonal antibody CC49.
Critical reviews in oncology/hematology 2001;38(1):3-16.
2001: Guadagni F; Kantor J; Aloe S; Carone M D; Spila A; D'Alessandro R; Abbolito M R; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner J W; Kashmiri S V; Steinberg S M; Roselli M; Schlom J
Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
Cancer research 2001;61(6):2523-32.
2001: Simon R M; Steinberg S M; Hamilton M; Hildesheim A; Khleif S; Kwak L W; Mackall C L; Schlom J; Topalian S L; Berzofsky J A
Clinical trial designs for the early clinical development of therapeutic cancer vaccines.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(6):1848-54.
2001: Sabzevari H; Kantor J; Jaigirdar A; Tagaya Y; Naramura M; Hodge J; Bernon J; Schlom J
Acquisition of CD80 (B7-1) by T cells.
Journal of immunology (Baltimore, Md. : 1950) 2001;166(4):2505-13.
2001: Kass E; Panicali D L; Mazzara G; Schlom J; Greiner J W
Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
Cancer research 2001;61(1):206-14.
2000: Arlen P; Tsang K Y; Marshall J L; Chen A; Steinberg S M; Poole D; Hand P H; Schlom J; Hamilton J M
The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines.
Cancer immunology, immunotherapy : CII 2000;49(10):517-29.
2000: Marshall J L; Hoyer R J; Toomey M A; Faraguna K; Chang P; Richmond E; Pedicano J E; Gehan E; Peck R A; Arlen P; Tsang K Y; Schlom J
Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(23):3964-73.
2000: Patel S D; Moskalenko M; Tian T; Smith D; McGuinness R; Chen L; Winslow G A; Kashmiri S; Schlom J; Stanners C P; Finer M H; McArthur J G
T-cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors.
Cancer gene therapy 2000;7(8):1127-34.
2000: Hodge J W; Rad A N; Grosenbach D W; Sabzevari H; Yafal A G; Gritz L; Schlom J
Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules.
Journal of the National Cancer Institute 2000;92(15):1228-39.
2000: Kass E; Parker J; Schlom J; Greiner J W
Comparative studies of the effects of recombinant GM-CSF and GM-CSF administered via a poxvirus to enhance the concentration of antigen- presenting cells in regional lymph nodes.
Cytokine 2000;12(7):960-71.
2000: Eder J P; Kantoff P W; Roper K; Xu G X; Bubley G J; Boyden J; Gritz L; Mazzara G; Oh W K; Arlen P; Tsang K Y; Panicali D; Schlom J; Kufe D W
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(5):1632-8.
2000: Salazar E; Zaremba S; Arlen P M; Tsang K Y; Schlom J
Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide.
International journal of cancer. Journal international du cancer 2000;85(6):829-38.
2000: Freund Y R; Mirsalis J C; Fairchild D G; Brune J; Hokama L A; Schindler-Horvat J; Tomaszewski J E; Hodge J W; Schlom J; Kantor J A; Tyson C A; Donohue S J
Vaccination with a recombinant vaccinia vaccine containing the B7-1 co-stimulatory molecule causes no significant toxicity and enhances T cell-mediated cytotoxicity.
International journal of cancer. Journal international du cancer 2000;85(4):508-17.
2000: Tamura M; Milenic D E; Iwahashi M; Padlan E; Schlom J; Kashmiri S V
Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(3):1432-41.
2000: Zhu M Z; Marshall J; Cole D; Schlom J; Tsang K Y
Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(1):24-33.
2000: Hodge J W; Schlom J
Costimulatory molecules in vaccine design.
Ernst Schering Research Foundation workshop 2000;(30):23-52.
1999: Schlom J; Tsang K Y; Kantor J A; Abrams S I; Zaremba S; Greiner J; Hodge J W
Strategies in the development of recombinant vaccines for colon cancer.
Seminars in oncology 1999;26(6):672-82.
1999: Hodge J W; Sabzevari H; Yafal A G; Gritz L; Lorenz M G; Schlom J
A triad of costimulatory molecules synergize to amplify T-cell activation.
Cancer research 1999;59(22):5800-7.
1999: Iwahashi M; Milenic D E; Padlan E A; Bei R; Schlom J; Kashmiri S V
CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity.
Molecular immunology 1999;36(15-16):1079-91.
1999: Meredith R F; Khazaeli M B; Macey D J; Grizzle W E; Mayo M; Schlom J; Russell C D; LoBuglio A F
Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3254s-3258s.
1999: Santos A D; Kashmiri S V; Hand P H; Schlom J; Padlan E A
Generation and characterization of a single gene-encoded single-chain-tetravalent antitumor antibody.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10 Suppl):3118s-3123s.
1999: Hodge J W; Schlom J
Comparative studies of a retrovirus versus a poxvirus vector in whole tumor-cell vaccines.
Cancer research 1999;59(20):5106-11.
1999: Conry R M; Khazaeli M B; Saleh M N; Allen K O; Barlow D L; Moore S E; Craig D; Arani R B; Schlom J; LoBuglio A F
Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: comparison of intradermal versus subcutaneous administration.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2330-7.
1999: Roselli M; Milenic D E; Brechbiel M W; Mirzadeh S; Pippin C G; Gansow O A; Colcher D; Schlom J
In vivo comparison of CHX-DTPA ligand isomers in athymic mice bearing carcinoma xenografts.
Cancer biotherapy & radiopharmaceuticals 1999;14(3):209-20.
1999: Morse M A; Deng Y; Coleman D; Hull S; Kitrell-Fisher E; Nair S; Schlom J; Ryback M E; Lyerly H K
A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(6):1331-8.
1999: Cutler M L; Shupert W L; Schlom J; Kantor J
Low-level transforming activity of an activated Ras gene under the control of a vaccinia virus p40 promoter is abrogated by truncation of the Ras cDNA.
Vaccine 1999;17(18):2275-83.
1999: Bristol J A; Schlom J; Abrams S I
Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
Cellular immunology 1999;194(1):78-89.
1999: Lorenz M G; Kantor J A; Schlom J; Hodge J W
Anti-tumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L).
Human gene therapy 1999;10(7):1095-103.
1999: Lorenz M G; Kantor J A; Schlom J; Hodge J W
Induction of anti-tumor immunity elicited by tumor cells expressing a murine LFA-3 analog via a recombinant vaccinia virus.
Human gene therapy 1999;10(4):623-31.
1999: Khleif S N; Abrams S I; Hamilton J M; Bergmann-Leitner E; Chen A; Bastian A; Bernstein S; Chung Y; Allegra C J; Schlom J
A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1999;22(2):155-65.
1999: Kalus R M; Kantor J A; Gritz L; Gómez Yafal A; Mazzara G P; Schlom J; Hodge J W
The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation.
Vaccine 1999;17(7-8):893-903.
1999: Kass E; Schlom J; Thompson J; Guadagni F; Graziano P; Greiner J W
Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.
Cancer research 1999;59(3):676-83.
1999: Marshall J L; Hawkins M J; Tsang K Y; Richmond E; Pedicano J E; Zhu M Z; Schlom J
Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):332-7.
1999: Lee H S; Shu L; De Pascalis R; Giuliano M; Zhu M; Padlan E A; Hand P H; Schlom J; Hong H J; Kashmiri S V
Generation and characterization of a novel single-gene-encoded single-chain immunoglobulin molecule with antigen binding activity and effector functions.
Molecular immunology 1999;36(1):61-71.
1999: McGuinness R P; Ge Y; Patel S D; Kashmiri S V; Lee H S; Hand P H; Schlom J; Finer M H; McArthur J G
Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor.
Human gene therapy 1999;10(2):165-73.
1998: Vogel K; Kantor J; Wood L; Rivera R; Schlom J
Oral immunization with enterocoated microbeads induces antigen-specific cytolytic T-cell responses.
Cellular immunology 1998;190(1):61-7.
1998: Schlom J; Tsang K Y; Kantor J A; Abrams S I; Zaremba S; Greiner J; Hodge J W
Cancer vaccine development.
Expert opinion on investigational drugs 1998;7(9):1439-52.
1998: Correale P; Walmsley K; Zaremba S; Zhu M; Schlom J; Tsang K Y
Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(6):3186-94.
1998: Bergmann-Leitner E S; Kantor J A; Shupert W L; Schlom J; Abrams S I
Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
Cellular immunology 1998;187(2):103-16.
1998: Bei R; Guptill V; Masuelli L; Kashmiri S V; Muraro R; Frati L; Schlom J; Kantor J
The use of a cationic liposome formulation (DOTAP) mixed with a recombinant tumor-associated antigen to induce immune responses and protective immunity in mice.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1998;21(3):159-69.
1998: Milenic D E; Roselli M; Brechbiel M W; Pippin C G; McMurray T J; Carrasquillo J A; Colcher D; Lambrecht R; Gansow O A; Schlom J
In vivo evaluation of a lead-labeled monoclonal antibody using the DOTA ligand.
European journal of nuclear medicine 1998;25(5):471-80.
1998: Bristol J A; Schlom J; Abrams S I
Development of a murine mutant Ras CD8+ CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties.
Journal of immunology (Baltimore, Md. : 1950) 1998;160(5):2433-41.
1997: Tsang K Y; Zhu M; Nieroda C A; Correale P; Zaremba S; Hamilton J M; Cole D; Lam C; Schlom J
Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(12 Pt 1):2439-49.
1997: Abrams S I; Khleif S N; Bergmann-Leitner E S; Kantor J A; Chung Y; Hamilton J M; Schlom J
Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Cellular immunology 1997;182(2):137-51.
1997: McLaughlin J P; Abrams S; Kantor J; Dobrzanski M J; Greenbaum J; Schlom J; Greiner J W
Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(6):449-59.
1997: Slavin-Chiorini D C; Kashmiri S V; Lee H S; Milenic D E; Poole D J; Bernon E; Schlom J; Hand P H
A CDR-grafted (humanized) domain-deleted antitumor antibody.
Cancer biotherapy & radiopharmaceuticals 1997;12(5):305-16.
1997: Zaremba S; Barzaga E; Zhu M; Soares N; Tsang K Y; Schlom J
Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
Cancer research 1997;57(20):4570-7.
1997: Guadagni F; Roselli M; Cosimelli M; Spila A; Cavaliere F; Arcuri R; D'Alessandro R; Fracasso P L; Casale V; Vecchione A; Casciani C U; Greiner J W; Schlom J
Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: lack of correlation.
International journal of cancer. Journal international du cancer 1997;72(6):949-54.
1997: Prasad G L; Lee H S; Iwahashi M; Milenic D E; Abrams S; Schlom J; Kashmiri S V
In vivo gene inoculation of a recombinant single-chain antitumor antibody induces anti-immunoglobulin response.
Cancer gene therapy 1997;4(4):253-9.
1997: Uzendoski K; Kantor J A; Abrams S I; Schlom J; Hodge J W
Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: induction and potentiation of antitumor responses.
Human gene therapy 1997;8(7):851-60.
1997: Liu T; Meredith R F; Saleh M N; Wheeler R H; Khazaeli M B; Plott W E; Schlom J; LoBuglio A F
Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in three phase II clinical trials.
Cancer biotherapy & radiopharmaceuticals 1997;12(2):79-87.
1997: Hodge J W; McLaughlin J P; Kantor J A; Schlom J
Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses.
Vaccine 1997;15(6-7):759-68.
1997: Alvarez R D; Partridge E E; Khazaeli M B; Plott G; Austin M; Kilgore L; Russell C D; Liu T; Grizzle W E; Schlom J; LoBuglio A F; Meredith R F
Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study.
Gynecologic oncology 1997;65(1):94-101.
1997: Correale P; Walmsley K; Nieroda C; Zaremba S; Zhu M; Schlom J; Tsang K Y
In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen.
Journal of the National Cancer Institute 1997;89(4):293-300.
1997: Abrams S I; Hodge J W; McLaughlin J P; Steinberg S M; Kantor J A; Schlom J
Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anticancer vaccine.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(1):48-59.
1997: Akagi J; Hodge J W; McLaughlin J P; Gritz L; Mazzara G; Kufe D; Schlom J; Kantor J A
Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(1):38-47.
1996: Schott M E; Wells D T; Schlom J; Abrams S I
Comparison of linear and branched peptide forms (MAPs) in the induction of T helper responses to point-mutated ras immunogens.
Cellular immunology 1996;174(2):199-209.
1996: Meredith R F; Khazaeli M B; Plott W E; Grizzle W E; Liu T; Schlom J; Russell C D; Wheeler R H; LoBuglio A F
Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(11):1811-8.
1996: Meredith R F; Partridge E E; Alvarez R D; Khazaeli M B; Plott G; Russell C D; Wheeler R H; Liu T; Grizzle W E; Schlom J; LoBuglio A F
Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1996;37(9):1491-6.
1996: Yu B; Carrasquillo J; Milenic D; Chung Y; Perentesis P; Feuerestein I; Eggensperger D; Qi C F; Paik C; Reynolds J; Grem J; Curt G; Siler K; Schlom J; Allegra C
Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(6):1798-809.
1996: McLaughlin J P; Schlom J; Kantor J A; Greiner J W
Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.
Cancer research 1996;56(10):2361-7.
1996: Abrams S I; Stanziale S F; Lunin S D; Zaremba S; Schlom J
Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.
European journal of immunology 1996;26(2):435-43.
1996: Abrams S I; Hand P H; Tsang K Y; Schlom J
Mutant ras epitopes as targets for cancer vaccines.
Seminars in oncology 1996;23(1):118-34.
1996: Schlom J; Kantor J; Abrams S; Tsang K Y; Panicali D; Hamilton J M
Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer.
Breast cancer research and treatment 1996;38(1):27-39.
1995: Mulligan T; Carrasquillo J A; Chung Y; Milenic D E; Schlom J; Feuerstein I; Paik C; Perentesis P; Reynolds J; Curt G
Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(12):1447-54.
1995: Shu L; Qi C F; Hand P H; Schlom J; Kashmiri S V
Generation and characterization of a single-gene encoded single-chain immunoglobulin-interleukin-2 fusion protein.
Immunotechnology : an international journal of immunological engineering 1995;1(3-4):231-41.
1995: Slavin-Chiorini D C; Kashmiri S V; Schlom J; Calvo B; Shu L M; Schott M E; Milenic D E; Snoy P; Carrasquillo J; Anderson K
Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins.
Cancer research 1995;55(23 Suppl):5957s-5967s.
1995: Kashmiri S V; Shu L; Padlan E A; Milenic D E; Schlom J; Hand P H
Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49.
Hybridoma 1995;14(5):461-73.
1995: Saleh M N; Khazaeli M B; Wheeler R H; Bucy R P; Liu T; Everson M P; Munn D H; Schlom J; LoBuglio A F
Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rhM-CSF) in patients with metastatic gastrointestinal cancer.
Cancer research 1995;55(19):4339-46.
1995: Bei R; Schlom J; Kashmiri S V
Baculovirus expression of a functional single-chain immunoglobulin and its IL-2 fusion protein.
Journal of immunological methods 1995;186(2):245-55.
1995: Hodge J W; Schlom J; Donohue S J; Tomaszewski J E; Wheeler C W; Levine B S; Gritz L; Panicali D; Kantor J A
A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate.
International journal of cancer. Journal international du cancer 1995;63(2):231-7.
1995: Abrams S I; Dobrzanski M J; Wells D T; Stanziale S F; Zaremba S; Masuelli L; Kantor J A; Schlom J; Masuelle L [corrected to Masuelli L ]
Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21.
European journal of immunology 1995;25(9):2588-97.
1995: Hodge J W; McLaughlin J P; Abrams S I; Shupert W L; Schlom J; Kantor J A
Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity.
Cancer research 1995;55(16):3598-603.
1995: Qi C F; Nieroda C; De Filippi R; Greiner J W; Correale P; Schlom J; Tsang K Y
Macrophage colony-stimulating factor enhancement of antibody-dependent cellular cytotoxicity against human colon carcinoma cells.
Immunology letters 1995;47(1-2):15-24.
1995: Tsang K Y; Zaremba S; Nieroda C A; Zhu M Z; Hamilton J M; Schlom J
Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine.
Journal of the National Cancer Institute 1995;87(13):982-90.
1995: Karr J F; Kantor J A; Hand P H; Eggensperger D L; Schlom J
The presence of prostate-specific antigen-related genes in primates and the expression of recombinant human prostate-specific antigen in a transfected murine cell line.
Cancer research 1995;55(11):2455-62.
1995: Roselli M; Hitchcock C L; Molinolo A; Milenic D E; Colcher D; Martin E W; Hinkle G H; Schlom J
Autoradiographic evaluation of radiolabeled monoclonal antibody B72.3 distribution in tumor and lymph nodes of adenocarcinoma patients.
Anticancer research 1995;15(3):975-84.
1995: Dansky-Ullmann C; Salgaller M; Adams S; Schlom J; Greiner J W
Synergistic effects of IL-6 and IFN-gamma on carcinoembryonic antigen (CEA) and HLA expression by human colorectal carcinoma cells: role for endogenous IFN-beta.
Cytokine 1995;7(2):118-29.
1995: Bei R; Paranavitana C; Milenic D; Kashmiri S V; Schlom J
Generation, purification, and characterization of a recombinant source of human prostate-specific antigen.
Journal of clinical laboratory analysis 1995;9(4):261-8.
1994: Bei R; Kantor J; Kashmiri S V; Abrams S; Schlom J
Enhanced immune responses and anti-tumor activity by baculovirus recombinant carcinoembryonic antigen (CEA) in mice primed with the recombinant vaccinia CEA.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(4):275-82.
1994: Yamaue H; Kashmiri S V; De Filippi R; Nieroda C; Yannelli J R; Tsang K Y; Schlom J
Enhanced interleukin-2 production in human tumor-infiltrating lymphocytes engineered by 3'-truncated interleukin-2 gene.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(4):262-74.
1994: Sawyer J R; Schlom J; Kashmiri S V
The effects of induction conditions on production of a soluble anti-tumor sFv in Escherichia coli.
Protein engineering 1994;7(11):1401-6.
1994: Hodge J W; Abrams S; Schlom J; Kantor J A
Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules.
Cancer research 1994;54(21):5552-5.
1994: Shimada S; Ogawa M; Takahashi M; Schlom J; Greiner J W
Molecular cloning and characterization of the complementary DNA of an M(r) 110,000 antigen expressed by human gastric carcinoma cells and upregulated by gamma-interferon.
Cancer research 1994;54(14):3831-6.
1994: Bei R; Kantor J; Kashmiri S V; Schlom J
Serological and biochemical characterization of recombinant baculovirus carcinoembryonic antigen.
Molecular immunology 1994;31(10):771-80.
1994: Meredith R F; Bueschen A J; Khazaeli M B; Plott W E; Grizzle W E; Wheeler R H; Schlom J; Russell C D; Liu T; LoBuglio A F
Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1994;35(6):1017-22.
1994: Primus F J; Finch M D; Wetzel S A; Masci A M; Schlom J; Kashmiri S V
Monoclonal antibody gene transfer. Implications for tumor-specific cell-mediated cytotoxicity.
Annals of the New York Academy of Sciences 1994;716():154-65; discussion 165-6.
1994: Conry R M; LoBuglio A F; Kantor J; Schlom J; Loechel F; Moore S E; Sumerel L A; Barlow D L; Abrams S; Curiel D T
Immune response to a carcinoembryonic antigen polynucleotide vaccine.
Cancer research 1994;54(5):1164-8.
1994: Greiner J W; Guadagni F; Roselli M; Ullmann C D; Nieroda C; Schlom J
Improved experimental radioimmunotherapy of colon xenografts by combining 131I-CC49 and interferon-gamma.
Diseases of the colon and rectum 1994;37(2 Suppl):S100-5.
1994: Schott M E; Schlom J; Siler K; Milenic D E; Eggensperger D; Colcher D; Cheng R; Kruper W J; Fordyce W; Goeckeler W
Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates.
Cancer 1994;73(3 Suppl):993-8.
1994: Hand P H; Kashmiri S V; Schlom J
Potential for recombinant immunoglobulin constructs in the management of carcinoma.
Cancer 1994;73(3 Suppl):1105-13.
1993: Abergel C; Padlan E A; Kashmiri S V; Milenic D; Calvo B; Schlom J
Crystallographic studies and primary structure of the antitumor monoclonal CC49 Fab'.
Proteins 1993;17(4):438-43.
1993: Saleh M N; Khazaeli M B; Grizzle W E; Wheeler R H; Lawson S; Liu T; Russel C; Meredith R; Schlom J; LoBuglio A F
A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer.
Cancer research 1993;53(19):4555-62.
1993: Meredith R F; Khazaeli M B; Grizzle W E; Orr R A; Plott G; Urist M M; Liu T; Russell C D; Wheeler R H; Schlom J
Direct localization comparison of murine and chimeric B72.3 antibodies in patients with colon cancer.
Human antibodies and hybridomas 1993;4(4):190-7.
1993: Shu L; Qi C F; Schlom J; Kashmiri S V
Secretion of a single-gene-encoded immunoglobulin from myeloma cells.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(17):7995-9.
1993: Kantor J; Abrams S; Irvine K; Snoy P; Kaufman H; Schlom J
Specific immunotherapy using a recombinant vaccinia virus expressing human carcinoembryonic antigen.
Annals of the New York Academy of Sciences 1993;690():370-3.
1993: Yokota T; Milenic D E; Whitlow M; Wood J F; Hubert S L; Schlom J
Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms.
Cancer research 1993;53(16):3776-83.
1993: Primus F J; Finch M D; Masci A M; Schlom J; Kashmiri S V
Self-reactive antibody expression by human carcinoma cells engineered with monoclonal antibody genes.
Cancer research 1993;53(14):3355-61.
1993: Salgaller M L; Bei R; Schlom J; Poole D J; Robbins P F
Baculovirus recombinants expressing the human carcinoembryonic antigen gene.
Cancer research 1993;53(9):2154-61.
1993: Tsang K Y; Kashmiri S V; Qi C F; Nieroda C; Calvo B; De Filippi R; Greiner J W; Primus F J; Schlom J
Transfer of the IL-6 gene into a human colorectal carcinoma cell line and consequent enhancement of tumor antigen expression.
Immunology letters 1993;36(2):179-85.
1993: Irvine K; Schlom J
Induction of delayed-type hypersensitivity responses by monoclonal anti-idiotypic antibodies to tumor cells expressing carcinoembryonic antigen and tumor-associated glycoprotein-72.
Cancer immunology, immunotherapy : CII 1993;36(5):281-92.
1993: Tsang K Y; Kashmiri S V; De Filippi R; Qi C F; Calvo B; Shu L; Nieroda C A; Greiner J W; Schlom J
A human T cell line engineered to secrete chimeric monoclonal antibody.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;13(3):143-52.
1993: Robbins P F; Eggensperger D; Qi C F; Schlom J
Definition of the expression of the human carcinoembryonic antigen and non-specific cross-reacting antigen in human breast and lung carcinomas.
International journal of cancer. Journal international du cancer 1993;53(6):892-7.
1993: Greiner J W; Ullmann C D; Nieroda C; Qi C F; Eggensperger D; Shimada S; Steinberg S M; Schlom J
Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with gamma-interferon.
Cancer research 1993;53(3):600-8.
1993: Slavin-Chiorini D C; Horan Hand P H; Kashmiri S V; Calvo B; Zaremba S; Schlom J
Biologic properties of a CH2 domain-deleted recombinant immunoglobulin.
International journal of cancer. Journal international du cancer 1993;53(1):97-103.
1993: Hand P H; Robbins P F; Salgaller M L; Poole D J; Schlom J
Evaluation of human carcinoembryonic-antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapies.
Cancer immunology, immunotherapy : CII 1993;36(2):65-75.
1993: Siler K; Eggensperger D; Hand P H; Milenic D E; Miller L S; Houchens D P; Hinkle G; Schlom J
Therapeutic efficacy of a high-affinity anticarcinoembryonic antigen monoclonal antibody (COL-1).
Biotechnology therapeutics 1993;4(3-4):163-81.
1993: Calvo B; Kashmiri S V; Hutzell P; Hand P H; Slavin-Chiorini D C; Schlom J; Zaremba S
Construction and purification of domain-deleted immunoglobulin variants of the recombinant/chimeric B72.3 (y1) monoclonal antibody.
Cancer biotherapy 1993;8(1):95-109.
1992: Kantor J; Irvine K; Abrams S; Snoy P; Olsen R; Greiner J; Kaufman H; Eggensperger D; Schlom J
Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate.
Cancer research 1992;52(24):6917-25.
1992: Ullmann C D; Schlom J; Greiner J W
Interleukin-6 increases carcinoembryonic antigen and histocompatibility leukocyte antigen expression on the surface of human colorectal carcinoma cells.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;12(4):231-41.
1992: Schott M E; Milenic D E; Yokota T; Whitlow M; Wood J F; Fordyce W A; Cheng R C; Schlom J
Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules.
Cancer research 1992;52(22):6413-7.
1992: Meredith R F; Khazaeli M B; Liu T; Plott G; Wheeler R H; Russell C; Colcher D; Schlom J; Shochat D; LoBuglio A F
Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1992;33(9):1648-53.
1992: Kantor J; Irvine K; Abrams S; Kaufman H; DiPietro J; Schlom J
Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine.
Journal of the National Cancer Institute 1992;84(14):1084-91.
1992: Yokota T; Milenic D E; Whitlow M; Schlom J
Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.
Cancer research 1992;52(12):3402-8.
1992: Greiner J W; Guadagni F; Goldstein D; Smalley R V; Borden E C; Simpson J F; Molinolo A; Schlom J
Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(5):735-46.
1992: Schlom J; Eggensperger D; Colcher D; Molinolo A; Houchens D; Miller L S; Hinkle G; Siler K
Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates.
Cancer research 1992;52(5):1067-72.
1992: Meredith R F; Khazaeli M B; Plott W E; Saleh M N; Liu T; Allen L F; Russell C D; Orr R A; Colcher D; Schlom J
Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1992;33(1):23-9.
1992: Horan Hand P; Simpson J F; Kuroki M; Parker R; Schlom J
Reactivities of an anti-CEA peptide monoclonal antibody.
The International journal of biological markers 1992;7(1):1-15.
1992: Hand P H; Calvo B; Milenic D; Yokota T; Finch M; Snoy P; Garmestani K; Gansow O; Schlom J; Kashmiri S V
Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant.
Cancer immunology, immunotherapy : CII 1992;35(3):165-74.
1992: Colcher D M; Milenic D E; Schlom J
Generation and characterization of monoclonal antibody B72.3. Experimental and preclinical studies.
Targeted diagnosis and therapy 1992;6():23-44.
1991: Milenic D E; Yokota T; Filpula D R; Finkelman M A; Dodd S W; Wood J F; Whitlow M; Snoy P; Schlom J
Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49.
Cancer research 1991;51(23 Pt 1):6363-71.
1991: Shimada S; Ogawa M; Schlom J; Greiner J W
Identification of a novel tumor-associated Mr 110,000 gene product in human gastric carcinoma cells that is immunologically related to carcinoembryonic antigen.
Cancer research 1991;51(20):5694-703.
1991: Greiner J W; Guadagni F; Goldstein D; Borden E C; Ritts R E; Witt P; LoBuglio A F; Saleh M N; Schlom J
Evidence for the elevation of serum carcinoembryonic antigen and tumor-associated glycoprotein-72 levels in patients administered interferons.
Cancer research 1991;51(16):4155-63.
1991: Kaufman H; Schlom J; Kantor J
A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA).
International journal of cancer. Journal international du cancer 1991;48(6):900-7.
1991: Robbins P F; Kantor J A; Salgaller M; Hand P H; Fernsten P D; Schlom J
Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line.
Cancer research 1991;51(14):3657-62.
1991: Schlom J; Siler K; Milenic D E; Eggensperger D; Colcher D; Miller L S; Houchens D; Cheng R; Kaplan D; Goeckeler W
Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetium-labeled immunoconjugate.
Cancer research 1991;51(11):2889-96.
1991: Guadagni F; Tortora G; Roselli M; Clair T; Cho-Chung Y S; Schlom J; Greiner J W
Carcinoembryonic antigen regulation in human colorectal tumor cells by a site-selective cyclic AMP analogue: a comparison with interferon-gamma.
International journal of cancer. Journal international du cancer 1991;48(3):413-22.
1991: Simpson J F; Primus F J; Schlom J
Complementation of expression of carcinoembryonic antigen and tumor associated glycoprotein-72 (TAG-72) in human colon adenocarcinomas.
The International journal of biological markers 1991;6(2):83-90.
1991: Pendurthi T K; Schlom J; Primus F J
Human lymphokine-activated killer cells augment immunotherapy of human colon carcinoma xenografts with monoclonal antibody D612.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(1):2-12.
1991: Fernsten P D; Primus F J; Greiner J W; Simpson J F; Schlom J
Characterization of the colorectal carcinoma-associated antigen defined by monoclonal antibody D612.
Cancer research 1991;51(3):926-34.
1991: Guadagni F; Roselli M; Schlom J; Greiner J W
Regulation of human tumor antigen expression by biological response modifiers (BRMs).
Annali dell'Istituto superiore di sanità 1991;27(1):71-8.
1991: Greiner J W; Smalley R V; Borden E C; Martin E W; Guadagni F; Roselli M; Schlom J
Applications of monoclonal antibodies and recombinant cytokines for the treatment of human colorectal and other carcinomas.
Journal of surgical oncology. Supplement 1991;2():9-13.
1991: Guadagni F; Schlom J; Greiner J W
In vitro and in vivo regulation of tumor antigen expression by human recombinant interferons.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1991;18(4):409-12.
1991: Schlom J; Milenic D E; Roselli M; Colcher D; Bird R; Johnson S; Hardman K D; Guadagni F; Greiner J W
New concepts in monoclonal antibody based radioimmunodiagnosis and radioimmunotherapy of carcinoma.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1991;18(4):425-35.
1991: Colcher D; Milenic D E; Ferroni P; Roselli M; Schlom J
In vivo and in vitro clinical applications of monoclonal antibodies against TAG-72.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1991;18(4):395-401.
1991: Roselli M; Schlom J; Gansow O A; Brechbiel M W; Mirzadeh S; Pippin C G; Milenic D E; Colcher D
Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal labeled monoclonal antibodies.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1991;18(4):389-94.
1991: Ferroni P; Milenic D E; Roselli M; Carrasquillo J A; Raubitschek A; Schlom J; Colcher D
Potential artifact for the increase of tumor associated antigens in serum samples from patients injected with monoclonal antibodies.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1991;18(4):383-7.
1991: Tsang K Y; Finch M D; Primus F J; Schlom J
Human recombinant interleukin-6 enhances antibody-dependent cellular cytotoxicity of human tumor cells mediated by human peripheral blood mononuclear cells.
Cancer immunology, immunotherapy : CII 1991;34(1):9-16.
1990: Pendurthi T K; Parker R; Schlom J; Primus F J
Lymphokine-activated killer cell cytotoxicity against human colon carcinomas enhanced by monoclonal antibody D612.
International journal of cancer. Journal international du cancer 1990;46(6):1021-8.
1990: Guadagni F; Witt P L; Robbins P F; Schlom J; Greiner J W
Regulation of carcinoembryonic antigen expression in different human colorectal tumor cells by interferon-gamma.
Cancer research 1990;50(19):6248-55.
1990: Ferroni P; Milenic D E; Roselli M; Carrasquillo J A; Raubitschek A; Schlom J; Colcher D
Potential for artifacts in monitoring for the detection of tumor associated antigens (TAG-72 and CEA) in serum from patients undergoing MAb-based diagnostic and therapeutic protocols.
The International journal of biological markers 1990;5(4):166-76.
1990: Katari R S; Fernsten P D; Schlom J
Characterization of the shed form of the human tumor-associated glycoprotein (TAG-72) from serous effusions of patients with different types of carcinomas.
Cancer research 1990;50(16):4885-90.
1990: Kuroki M; Fernsten P D; Wunderlich D; Colcher D; Simpson J F; Poole D J; Schlom J
Serological mapping of the TAG-72 tumor-associated antigen using 19 distinct monoclonal antibodies.
Cancer research 1990;50(16):4872-9.
1990: Colcher D; Bird R; Roselli M; Hardman K D; Johnson S; Pope S; Dodd S W; Pantoliano M W; Milenic D E; Schlom J
In vivo tumor targeting of a recombinant single-chain antigen-binding protein.
Journal of the National Cancer Institute 1990;82(14):1191-7.
1990: Colcher D; Milenic D E; Ferroni P; Carrasquillo J A; Reynolds J C; Roselli M; Larson S M; Schlom J
In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1990;31(7):1133-42.
1990: Schlom J; Molinolo A; Simpson J F; Siler K; Roselli M; Hinkle G; Houchens D P; Colcher D
Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy.
Journal of the National Cancer Institute 1990;82(9):763-71.
1990: Molinolo A; Simpson J F; Thor A; Schlom J
Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue.
Cancer research 1990;50(4):1291-8.
1990: Schlom J; Hand P H; Greiner J W; Colcher D; Shrivastav S; Carrasquillo J A; Reynolds J C; Larson S M; Raubitschek A
Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting.
Cancer research 1990;50(3 Suppl):820s-827s.
1990: Primus F J; Pendurthi T K; Hutzell P; Kashmiri S; Slavin D C; Callahan R; Schlom J
Chimeric B72.3 mouse/human (IgG1) antibody directs the lysis of tumor cells by lymphokine-activated killer cells.
Cancer immunology, immunotherapy : CII 1990;31(6):349-57.
1990: Ferroni P; Milenic D E; Schlom J; Colcher D
Assay for the detection of anti-idiotypic antibodies to monoclonal antibody B72.3.
Journal of clinical laboratory analysis 1990;4(6):465-73.
1990: Schlom J; Siler K; Colcher D; Carrasquillo J A; Reynolds J C; Sugarbaker P; Larson S M
Binding of radiolabeled MAb B72.3 administered intravenously and intraperitoneally in colorectal cancer patients. An overview.
Acta radiologica. Supplementum 1990;374():123-8.
1989: Kuroki M; Greiner J W; Simpson J F; Primus F J; Guadagni F; Schlom J
Serologic mapping and biochemical characterization of the carcinoembryonic antigen epitopes using fourteen distinct monoclonal antibodies.
International journal of cancer. Journal international du cancer 1989;44(2):208-18.
1989: Roselli M; Schlom J; Gansow O A; Raubitschek A; Mirzadeh S; Brechbiel M W; Colcher D
Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1989;30(5):672-82.
1989: Kantor J; Tran R; Greiner J; Pestka S; Fisher P B; Shively J E; Schlom J
Modulation of carcinoembryonic antigen messenger RNA levels in human colon carcinoma cells by recombinant human gamma-interferon.
Cancer research 1989;49(10):2651-5.
1989: Colcher D; Milenic D; Roselli M; Raubitschek A; Yarranton G; King D; Adair J; Whittle N; Bodmer M; Schlom J
Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3.
Cancer research 1989;49(7):1738-45.
1989: Muraro R; Nuti M; Natali P G; Bigotti A; Simpson J F; Primus F J; Colcher D; Greiner J W; Schlom J
A monoclonal antibody (D612) with selective reactivity for malignant and normal gastro-intestinal epithelium.
International journal of cancer. Journal international du cancer 1989;43(4):598-607.
1989: Guadagni F; Schlom J; Johnston W W; Szpak C A; Goldstein D; Smalley R; Simpson J F; Borden E C; Pestka S; Greiner J W
Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells.
Journal of the National Cancer Institute 1989;81(7):502-12.
1989: Shrivastav S; Schlom J; Raubitschek A; Molinolo A; Simpson J; Hand P H
Studies concerning the effect of external irradiation on localization of radiolabeled monoclonal antibody B72.3 to human colon carcinoma xenografts.
International journal of radiation oncology, biology, physics 1989;16(3):721-9.
1989: Mariani-Costantini R; Theillet C; Hutzell P; Merlo G; Schlom J; Callahan R
In situ detection of c-myc mRNA in adenocarcinomas, adenomas, and mucosa of human colon.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1989;37(3):293-8.
1989: Schlom J; Colcher D; Szpak C A; Johnston W W; Sugarbaker P; Carrasquillo J A; Reynolds J C; Larson S M
A monoclonal antibody (B72.3) to adenocarcinoma of the colon and related tumors.
Progress in clinical and biological research 1989;288():63-72.
1989: Larson S M; Raubitschek A; Reynolds J C; Neumann R D; Hellstrom K E; Hellstrom I; Colcher D; Schlom J; Glatstein E; Carrasquillo J A
Comparison of bone marrow dosimetry and toxic effect of high dose 131I-labeled monoclonal antibodies administered to man.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1989;16(2):153-8.
1989: Schlom J; Colcher D; Roselli M; Carrasquillo J A; Reynolds J C; Larson S M; Sugarbaker P; Tuttle S E; Martin E W
Tumor targeting with monoclonal antibody B72.3.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1989;16(2):137-42.
1989: Callahan R; Weeks M O; Ohuchi N; Schlom J
Retroviral-related genes, proto-oncogenes, and breast cancer.
Immunology series 1989;43():623-42.
1988: Sheer D G; Schlom J; Cooper H L
Purification and composition of the human tumor-associated glycoprotein (TAG-72) defined by monoclonal antibodies CC49 and B72.3.
Cancer research 1988;48(23):6811-8.
1988: Tran R; Kashmiri S V; Kantor J; Greiner J W; Pestka S; Shively J E; Schlom J
Correlation of DNA hypomethylation with expression of carcinoembryonic antigen in human colon carcinoma cells.
Cancer research 1988;48(20):5674-9.
1988: Colcher D; Minelli M F; Roselli M; Muraro R; Simpson-Milenic D; Schlom J
Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies.
Cancer research 1988;48(16):4597-603.
1988: Thor A; Viglione M J; Ohuchi N; Simpson J; Steis R; Cousar J; Lippman M; Kufe D W; Schlom J
Comparison of monoclonal antibodies for the detection of occult breast carcinoma metastases in bone marrow.
Breast cancer research and treatment 1988;11(2):133-45.
1988: Carrasquillo J A; Sugarbaker P; Colcher D; Reynolds J C; Esteban J; Bryant G; Perentesis P; Yokoyama K; Rotman M; Schlom J
Peritoneal carcinomatosis: imaging with intraperitoneal injection of I-131-labeled B72.3 monoclonal antibody.
Radiology 1988;167(1):35-40.
1988: Tran R; Hand P H; Greiner J W; Pestka S; Schlom J
Enhancement of surface antigen expression on human breast carcinoma cells by recombinant human interferons.
Journal of interferon research 1988;8(1):75-88.
1988: Guadagni F; Schlom J; Pothen S; Pestka S; Greiner J W
Parameters involved in the enhancement of monoclonal antibody targeting in vivo with recombinant interferon.
Cancer immunology, immunotherapy : CII 1988;26(3):222-30.
1987: Whittle N; Adair J; Lloyd C; Jenkins L; Devine J; Schlom J; Raubitschek A; Colcher D; Bodmer M
Expression in COS cells of a mouse-human chimaeric B72.3 antibody.
Protein engineering 1987;1(6):499-505.
1987: Ohuchi N; Simpson J F; Colcher D; Schlom J
Complementation of anti-CEA and anti-TAG-72 monoclonal antibodies in reactivity to human gastric adenocarcinomas.
International journal of cancer. Journal international du cancer 1987;40(6):726-33.
1987: Colcher D; Esteban J; Carrasquillo J A; Sugarbaker P; Reynolds J C; Bryant G; Larson S M; Schlom J
Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma.
Cancer research 1987;47(15):4218-24.
1987: Ohuchi N; Wunderlich D; Fujita J; Colcher D; Muraro R; Nose M; Schlom J
Differential expression of carcinoembryonic antigen in early gastric adenocarcinomas versus benign gastric lesions defined by monoclonal antibodies reactive with restricted antigen epitopes.
Cancer research 1987;47(13):3565-71.
1987: Hand P H; Vilasi V; Thor A; Ohuchi N; Schlom J
Quantitation of Harvey ras p21 enhanced expression in human breast and colon carcinomas.
Journal of the National Cancer Institute 1987;79(1):59-65.
1987: Ohuchi N; Page D L; Merino M J; Viglione M J; Kufe D W; Schlom J
Expression of tumor-associated antigen (DF3) in atypical hyperplasias and in situ carcinomas of the human breast.
Journal of the National Cancer Institute 1987;79(1):109-17.
1987: Esteban J M; Schlom J; Mornex F; Colcher D
Radioimmunotherapy of athymic mice bearing human colon carcinomas with monoclonal antibody B72.3: histological and autoradiographic study of effects on tumors and normal organs.
European journal of cancer & clinical oncology 1987;23(6):643-55.
1987: Ohuchi N; Hand P H; Merlo G; Fujita J; Mariani-Costantini R; Thor A; Nose M; Callahan R; Schlom J
Enhanced expression of c-Ha-ras p21 in human stomach adenocarcinomas defined by immunoassays using monoclonal antibodies and in situ hybridization.
Cancer research 1987;47(5):1413-20.
1987: Colcher D; Esteban J M; Carrasquillo J A; Sugarbaker P; Reynolds J C; Bryant G; Larson S M; Schlom J
Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients.
Cancer research 1987;47(4):1185-9.
1987: Esteban J M; Colcher D; Sugarbaker P; Carrasquillo J A; Bryant G; Thor A; Reynolds J C; Larson S M; Schlom J
Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3.
International journal of cancer. Journal international du cancer 1987;39(1):50-9.
1987: Muraro R; Wunderlich D; Thor A; Cunningham R; Noguchi P; Schlom J
Immunological characterization of a novel human colon-associated antigen (CAA) by a monoclonal antibody.
International journal of cancer. Journal international du cancer 1987;39(1):34-44.
1987: Thor A; Muraro R; Gorstein F; Ohuchi N; Viglione M; Szpak C A; Johnston W W; Schlom J
Adjunct to the diagnostic distinction between adenocarcinomas of the ovary and the colon utilizing a monoclonal antibody (COL-4) with restricted carcinoembryonic antigen reactivity.
Cancer research 1987;47(2):505-12.
1987: Colcher D; Carrasquillo J A; Esteban J M; Sugarbaker P; Reynolds J C; Siler K; Bryant G; Larson S M; Schlom J
Radiolabeled monoclonal antibody B72.3 localization in metastatic lesions of colorectal cancer patients.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1987;14(3):251-62.
1987: Thor A; Viglione M J; Muraro R; Ohuchi N; Schlom J; Gorstein F
Monoclonal antibody B72.3 reactivity with human endometrium: a study of normal and malignant tissues.
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 1987;6(3):235-47.
1986: Thor A; Weeks M O; Schlom J
Monoclonal antibodies and breast cancer.
Seminars in oncology 1986;13(4):393-401.
1986: Caruso A; Schlom J; Vilasi V; Weeks M O; Hand P H
Development of quantitative liquid competition radioimmunoassays for the ras oncogene and proto-oncogene p21 products.
International journal of cancer. Journal international du cancer 1986;38(4):587-95.
1986: Theillet C; Lidereau R; Escot C; Hutzell P; Brunet M; Gest J; Schlom J; Callahan R
Loss of a c-H-ras-1 allele and aggressive human primary breast carcinomas.
Cancer research 1986;46(9):4776-81.
1986: Martin S E; Moshiri S; Thor A; Vilasi V; Chu E W; Schlom J
Identification of adenocarcinoma in cytospin preparations of effusions using monoclonal antibody B72.3.
American journal of clinical pathology 1986;86(1):10-8.
1986: Thor A; Gorstein F; Ohuchi N; Szpak C A; Johnston W W; Schlom J
Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3.
Journal of the National Cancer Institute 1986;76(6):995-1006.
1986: Thor A; Ohuchi N; Szpak C A; Johnston W W; Schlom J
Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3.
Cancer research 1986;46(6):3118-24.
1986: Ohuchi N; Thor A; Page D L; Hand P H; Halter S A; Schlom J
Expression of the 21,000 molecular weight ras protein in a spectrum of benign and malignant human mammary tissues.
Cancer research 1986;46(5):2511-9.
1985: Muraro R; Wunderlich D; Thor A; Lundy J; Noguchi P; Cunningham R; Schlom J
Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues.
Cancer research 1985;45(11 Pt 2):5769-80.
1985: Horan Hand P; Colcher D; Salomon D; Ridge J; Noguchi P; Schlom J
Influence of spatial configuration of carcinoma cell populations on the expression of a tumor-associated glycoprotein.
Cancer research 1985;45(2):833-40.
1985: Schlom J; Colcher D; Hand P H; Greiner J; Wunderlich D; Weeks M; Fisher P B; Noguchi P; Pestka S; Kufe D
Monoclonal antibodies reactive with breast tumor-associated antigens.
Advances in cancer research 1985;43():143-73.
1984: Schlom J; Greiner J; Hand P H; Colcher D; Inghirami G; Weeks M; Pestka S; Fisher P B; Noguchi P; Kufe D
Monoclonal antibodies to breast cancer-associated antigens as potential reagents in the management of breast cancer.
Cancer 1984;54(11 Suppl):2777-94.
1984: Thor A; Horan Hand P; Wunderlich D; Caruso A; Muraro R; Schlom J
Monoclonal antibodies define differential ras gene expression in malignant and benign colonic diseases.
Nature 1984;311(5986):562-5.
1984: Greiner J W; Hand P H; Noguchi P; Fisher P B; Pestka S; Schlom J
Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment.
Cancer research 1984;44(8):3208-14.
1984: Hand P H; Thor A; Wunderlich D; Muraro R; Caruso A; Schlom J
Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas.
Proceedings of the National Academy of Sciences of the United States of America 1984;81(16):5227-31.
1984: McCoy J L; Tagliabue A; Ames R E; Teramoto Y A; Cannon G B; Alford C; Herberman R B; Schlom J
Indirect leukocyte migration inhibition in breast cancer and benign breast disease patients by mouse mammary tumor virus grown in feline kidney cells.
Journal of the National Cancer Institute 1984;72(3):569-76.
1983: Colcher D; Hand P H; Wunderlich D; Nuti M; Teramoto Y A; Kufe D; Schlom J
Monoclonal antibodies to human mammary carcinoma associated antigens and their potential uses for diagnosis, prognosis, and therapy.
Laboratory and research methods in biology and medicine 1983;8():215-58.
1983: Horan Hand P; Colcher D; Wunderlich D; Nuti M; Teramoto Y A; Schlom J
Non-HLA antigens in breast cancer.
Progress in clinical and biological research 1983;133():115-24.
1982: Teramoto Y A; Meriani R; Wunderlich D; Schlom J
The immunohistochemical reactivity of a human monoclonal antibody with tissue sections of human mammary tumors.
Cancer 1982;50(2):241-9.
1982: Nuti M; Teramoto Y A; Mariani-Costantini R; Hand P H; Colcher D; Schlom J
A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations.
International journal of cancer. Journal international du cancer 1982;29(5):539-45.
1981: Wunderlich D; Teramoto Y A; Alford C; Schlom J
The use of lymphocytes from axillary lymph nodes of mastectomy patients to generate human monoclonal antibodies.
European journal of cancer & clinical oncology 1981;17(7):719-30.
1981: Colcher D; Horan Hand P; Teramoto Y A; Wunderlich D; Schlom J
Use of monoclonal antibodies to define the diversity of mammary tumor viral gene products in virions and mammary tumors of the genus Mus.
Cancer research 1981;41(4):1451-9.
1980: Schlom J; Wunderlich D; Teramoto Y A
Generation of human monoclonal antibodies reactive with human mammary carcinoma cells.
Proceedings of the National Academy of Sciences of the United States of America 1980;77(11):6841-5.
1980: Teramoto Y A; Hand P H; Callahan R; Schlom J
Detection of novel murine mammary tumor viruses by interspecies immunoassays.
Journal of the National Cancer Institute 1980;64(4):967-75.
1980: Hand P H; Teramoto Y A; Callahan R; Schlom J
Interspecies radioimmunoassay for the major internal protein of mammary tumor viruses.
Virology 1980;101(1):61-71.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Jeffrey Schlom

Research Profile (preview)

Living Beings

Chemicals & Drugs

Disorders

Anatomy

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Jeffrey Schlom (preview)

All Publications